Close Menu

head and neck cancer

Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.

The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.

The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.

A Sanford Cancer Center team is genomically profiling head and neck squamous cell cancer samples to look for biomarkers of immunotherapy and chemoradiation response.

Researchers will use the funds to explore if the device can deplete circulating exosomes and make head and neck cancer patients more responsive to treatments.

In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors. 

Preclinical studies showed that combining CUE-101 with an anti-PD1 checkpoint inhibitor could increase anti-tumor efficacy in advanced HPV-positive head and neck tumors.

The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.

Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.

Transgene and NEC are working together to use artificial intelligence to tailor immunotherapy to individual patients.

Pages